Evidence map›Paper›PMID 34764696›Full record

ArticleCancer management and research2021

Development and Evaluation of Serum CST1 Detection for Early Diagnosis of Esophageal Squamous Cell Carcinoma.

Jianwei Wang, Lili Yu, Yulong Sun, Liangming Zhang, Mingshu Tu, Liqing Cai, Xiaoqing Yin, Xiaojie Pan, Tao Wang, Yi Huang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer management and research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Jianwei Wang *Provincial Clinical College, Fujian Medical University, Fuzhou, 350001, People's Republic of China.
Lili Yu *Provincial Clinical College, Fujian Medical University, Fuzhou, 350001, People's Republic of China.
Yulong Sun *Shanghai Liangrun Biomedicine Technology Limited Company, Shanghai, 200000, People's Republic of China.
Liangming ZhangProvincial Clinical College, Fujian Medical University, Fuzhou, 350001, People's Republic of China.
Mingshu TuProvincial Clinical College, Fujian Medical University, Fuzhou, 350001, People's Republic of China.
Liqing CaiProvincial Clinical College, Fujian Medical University, Fuzhou, 350001, People's Republic of China.
Xiaoqing YinDepartment of Clinical Laboratory, Fujian Provincial Hospital, Fuzhou, 350001, People's Republic of China.
Xiaojie PanProvincial Clinical College, Fujian Medical University, Fuzhou, 350001, People's Republic of China.
Tao WangShanghai Liangrun Biomedicine Technology Limited Company, Shanghai, 200000, People's Republic of China.ORCID 0000-0002-8531-9904
Yi HuangProvincial Clinical College, Fujian Medical University, Fuzhou, 350001, People's Republic of China.ORCID 0000-0001-7273-8301
Fujian Medical University · CNShanghai Liangyou (China) · CNFujian University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeOur pilot study has shown that cystatin SN (CST1) protein is highly expressed in esophageal squamous cell carcinoma (ESCC) tissues. We intend to develop a chemiluminescent enzyme immunoassay (CLEIA) available for serum CST1 detection and define the diagnostic value of CST1 detection for early ESCC patients, and establish a panel of CST1 with traditional tumor markers to improve the diagnostic sensitivity for early ESCC.

methodsDetection performance of CLEIA for CST1 was evaluated by linearity, detection limit, accuracy, precision, anti-interference and stability. Diagnostic performance of CST1 for early ESCC was evaluated by detecting CST1 of 112 early ESCC, 107 esophageal benign lesions (EBL), and 151 healthy controls (HC). CEA, CYFRA21-1 and SCC-Ag were detected by chemiluminescence immunoassay (CLIA).

resultsThe linear range and detection limit of CLEIA for CST1 were 6.25-400 pg/mL and 1.35 pg/mL, respectively; the average recovery rate was 102.65%; CVs of intra-batch precision and inter-batch precision were <1/4 TEa and <1/3 TEa, respectively; 8 interferents including 7 common interferents and CST4 had no interference on CST1 detection; stability evaluation showed good sample and reagent stability. The level and positive rate of CST1 in early ESCC group were significantly higher than those in EBL/HC groups (

conclusionCLEIA has excellent detection performance for CST1. CST1 might be a prospective serological biomarker for early diagnosis of ESCC, while combination of CST1 and CEA, SCC-Ag might improve the early diagnostic performance.

Indexed as

chemiluminescence enzyme immunoassaycystatin SNearly diagnosisesophageal squamous cell carcinomamethodological evaluation

Identifiers

PMID34764696
PMCPMC8577471
OpenAlexW3213473737

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.